Anti-EGFR therapy in first-line colorectal cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 10, 2011, Pages 1499-1503

  Lamas, Maria J ^a   Duran, Goretti ^a   Gallardo, Elena ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Complejo Hospitalario of Pontevedra ^*  (Spain)

Author keywords

cetuximab; colorectal cancer; EGFR; KRAS; oxaliplatin

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TUMOR MARKER;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGICAL COMPLICATION; NEUTROPENIA; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SKIN DISEASE; THROMBOCYTOPENIA; WILD TYPE;

EID: 80054765305     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.149     Document Type: Article

References (21)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Büchler M W. Colorectal cancer. Lancet 365(9454), 153-165 (2005). (Pubitemid 40091806)
2. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: amodel to predict long-term survival. Ann. Surg. 240(4), 644-657 (2004).
3. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004). (Pubitemid 41095086)
4. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal caner. N. Engl. J. Med. 351, 337-345 (2004). (Pubitemid 38944402)
5. Sobrero AF, Fehrenbacher L, Rivera F et al. Randomized Phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial (Abstract LB-2). Presented at: American Association for Cancer Research: 98th Annual Meeting. Los Angeles, CA, USA, 14-18 April 2007.
6. Jonker DJ, Karapetis CS, Moore M et al. Randomized Phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG) [Abstract LB-1]. Presented at: American Association for Cancer Research: 98th Annual Meeting. Los Angeles, CA, USA, 14-18 April 2007.
7. Vincenzi B, Santini D, Rabitti C et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer 94, 792-797 (2006).
8. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
9. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the frst-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
10. Porebska I, Harlozmska A, Bojarowski T et al. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumor Biol. 21(2), 105-115 (2000). (Pubitemid 30114656)
11. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab effcacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
12. Kohne C, Rougier P, Stroh C et al Cetuximab with chemotherapy (CT) as frst-line treatment for metastatic colorectal cancer (mCRC): a meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO (Abstract 406). Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 22-24 January 2010
13. Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial. J. Clin. Oncol. 29(Suppl. 4) (2011).
14. Folprecht G, Gruenberger T, Hartmann JT et al. Randomized multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CLM). Ann. Oncol. 19(8), 168 (2008) (Abstract 510PD).
15. Ciuleanu T, Nikolic V, Shmueli E et al Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as frst-line therapy in patients (pts) with KRA S wild-type (wt) metastatic colorectal cancer (mCRC). J. Clin. Oncol. 29(Suppl. 4) (2011) (Abstract 494).
16. Laurent-Puig, Cayre A, Manceau G et al Analysis of PTEN, BRAF, and EGFR status in determining beneft from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27(35), 5924-5930 (2009).
17. De Roock W, Jonker D, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16), 1812-1820 (2010).
18. Simon R. Optimal two-stage designs for Phase II clinical trials. Control. Clin. Trials 10(1), 1-10 (1989). (Pubitemid 19099520)
19. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the effcacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8), 753-762 (2010).
20. Negri FV, Bozzetti C, Lagrasta CA et al. PTEN status in advanced colorectal cancer treated with cetuximab. Br. J. Cancer 102(1), 162-164 (2010).
21. Lamas MJ, Duran G, Balboa E et al. Use of a comprehensive panel of biomarkers to predict response to a fuorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics 12(3), 433-442 (2011).